Mortality in the beta blocker heart attack trial: circumstances surrounding death
RW Peters, R Byington, D Arensberg… - Journal of Chronic …, 1987 - Elsevier
Abstract In the Beta Blocker Heart Attack Trial, a double blind, randomized, controlled study,
patients taking propranolol (180 or 240 mg/day) initiated 5–21 days post myocardial
infarction had 26% fewer deaths than those taking placebo over a 25 month (mean)
followup. Detailed analysis of the circumstances surrounding the BHAT deaths failed to
reveal any striking difference between propranolol and placebo in the type of clinical event
preceding death, the incidence and type of acute and prodromal signs and symptoms, the …
patients taking propranolol (180 or 240 mg/day) initiated 5–21 days post myocardial
infarction had 26% fewer deaths than those taking placebo over a 25 month (mean)
followup. Detailed analysis of the circumstances surrounding the BHAT deaths failed to
reveal any striking difference between propranolol and placebo in the type of clinical event
preceding death, the incidence and type of acute and prodromal signs and symptoms, the …